Developer docs
API playgroundTry for free, no card

Search company profiles

Trevi Therapeutics

Full company profile

uuid0000n44

Namestring
Trevi Therapeutics
Legal namestring
Trevi Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Trevi Therapeutics is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in New Haven, Connecticut, listed on NASDAQ under the ticker TRVI. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, a dual-acting opioid with a KAMA (kappa opioid receptor agonist and mu opioid receptor antagonist) mechanism. Trevi is targeting chronic cough in three distinct patient populations: idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The CORAL Phase 2b trial in IPF chronic cough was published in JAMA in January 2026, and the company completed an End-of-Phase 2 meeting with the FDA in March 2026, with Phase 3 trials planned to initiate in the second half of 2026 across all three indications.

The company's core technology is the reformulation of nalbuphine into an oral extended-release product, combined with the novel application of the KAMA mechanism to chronic cough pathways. Trevi holds 24 issued US and foreign patents covering formulations and methods of use, with a key composition-of-matter patent extending protection to 2039. There are currently no FDA-approved therapies for chronic cough in IPF or RCC, positioning Haduvio as a potential first-in-class therapy in these underserved indications. The addressable patient population is estimated at approximately 140,000 IPF patients and 2-5 million RCC patients in the US.

Trevi is pre-revenue and operates a capital-intensive clinical development business model funded primarily through public equity offerings. The company raised approximately $115.1 million in June 2025 and approximately $150 million in April 2026, bringing pro forma cash to roughly $334 million as of Q1 2026. With a market capitalization of approximately $2.56 billion and 95.76% institutional ownership, Trevi is in a Phase 3 preparation phase, building out commercial leadership (including a new CFO and CCO) in anticipation of a potential first US launch. The company employs 11-50 people and is expected to generate its first commercial revenue following Haduvio's potential regulatory approval, likely via specialty pharmacy distribution to pulmonologists and cough specialists.

Short descriptiontext

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release nalbuphine therapy targeting chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients, with Phase 3 trials planned to begin in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chronic cough therapeutics, respiratory biopharmaceuticals, clinical-stage biotechnology, opioid receptor modulators, extended-release drug development
Industry1 code
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Respiratory Therapeutics
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Haduvio
Description

Oral nalbuphine ER therapy for chronic cough conditions including IPF-related chronic cough, non-IPF ILD, and refractory chronic cough. Novel KAMA mechanism acting as kappa agonist and mu antagonist targeting opioid receptors along the cough reflex arc.

trevitherapeutics.com
Core offering1 text field

Trevi Therapeutics develops Haduvio (nalbuphine ER), an investigational oral extended-release therapy that acts as a kappa agonist and mu antagonist (KAMA) targeting opioid receptors along the cough reflex arc both centrally and peripherally. The therapy is being advanced through late-stage clinical development for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC). Haduvio is not yet approved by any regulatory authority.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 60.2% reduction in 24-hour cough frequency from baseline at 108mg BID dose (p<0.0001) vs 16.9% for placebo in IPF patients
+4 more records
Product overview1 text field

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single investigational therapy, Haduvio (nalbuphine ER), an oral extended-release formulation targeting chronic cough conditions. Haduvio acts as a kappa agonist and mu antagonist (KAMA), working both centrally and peripherally along the cough reflex arc. The company is pursuing development for three indications: chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is not yet approved by any regulatory authority.

Product and service1 record
1Haduvio (nalbuphine ER)
CategoryChronic Cough Therapeutics
Description

Haduvio is an investigational oral extended-release nalbuphine therapy that acts as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors along the cough reflex arc both centrally and peripherally. It is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The therapy demonstrated statistically significant reductions in cough frequency in Phase 2b CORAL and Phase 2a RIVER trials. Not yet approved by any regulatory authority.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GSK acquired Bellus Health in 2023 to advance camlipixant (BLU-5937), a P2X3 antagonist in Phase 3 development for refractory chronic cough — the most directly competing late-stage chronic cough program to Trevi's Haduvio (nalbuphine ER).

TypeDirect peer
Description

Bayer acquired NeRRe Therapeutics to develop eliapixant and orvepitant for refractory chronic cough; while Bayer later halted the eliapixant program, it remains a direct comparator in the chronic cough therapeutic space alongside GSK's camlipixant.

TypeDirect peer
Description

Merck acquired Afferent Pharmaceuticals and advanced gefapixant (MK-7264) — a P2X3 antagonist — for refractory chronic cough. Although Merck withdrew the original FDA application in 2022, the program represents the most direct historical precedent for Haduvio's commercialization trajectory.

4Boehringer Ingelheim
TypeBroad incumbent
Description

Boehringer Ingelheim markets OFEV (nintedanib) and Esbriet (pirfenidone) — the two FDA-approved therapies for idiopathic pulmonary fibrosis. As the incumbent in Trevi's primary IPF-CC indication, BI is the dominant specialist prescriber base that any Haduvio launch would need to leverage.

TypeDirect peer
Description

Pliant Therapeutics is a clinical-stage biotech developing integrin inhibitors (bexotegrast/PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, directly overlapping Trevi's IPF patient population and competing for the same pulmonology specialty prescribing audience.

TypeBroad incumbent
Description

United Therapeutics is a specialty pharmaceutical company with a dominant pulmonary hypertension franchise (Tyvaso, Remodulin) and orphan/rare disease focus, serving as a public-market comparable for capital-efficient pulmonary specialty pharma business models.

TypeBroad incumbent
Description

Insmed is a specialty pulmonary pharmaceutical company (brensocatib for bronchiectasis, ARIKAYCE for NTM lung infection) with a similar orphan/rare pulmonary disease commercialization playbook and late-stage clinical assets targeting underserved pulmonary indications.

TypeDirect peer
Description

FibroGen developed pamrevlumab (anti-CTGF) for idiopathic pulmonary fibrosis and other fibrotic diseases — sharing Trevi's IPF patient population and clinical development path, providing a relevant benchmark for IPF therapeutic clinical readouts.

TypeDirect peer
Description

Bayer's NeRRe-derived eliapixant (P2X3 antagonist for chronic cough) halted Phase 3 in 2023; Bayer serves as both a precedent (Merck withdrawal) and direct mechanism-class competitor to Haduvio in chronic cough.

TypeEmerging player
Description

Shionogi has historically been active in cough therapeutics (codeine-based formulations and novel cough candidates) in Asia and selectively in the US, representing a partial-overlap chronic cough competitor with regional strength.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trevi Therapeutics

Respiratory Therapeuticstrevitherapeutics.com

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release nalbuphine therapy targeting chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients, with Phase 3 trials planned to begin in 2026.

What Trevi Therapeutics does

Trevi Therapeutics is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in New Haven, Connecticut, listed on NASDAQ under the ticker TRVI. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, a dual-acting opioid with a KAMA (kappa opioid receptor agonist and mu opioid receptor antagonist) mechanism. Trevi is targeting chronic cough in three distinct patient populations: idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The CORAL Phase 2b trial in IPF chronic cough was published in JAMA in January 2026, and the company completed an End-of-Phase 2 meeting with the FDA in March 2026, with Phase 3 trials planned to initiate in the second half of 2026 across all three indications.

The company's core technology is the reformulation of nalbuphine into an oral extended-release product, combined with the novel application of the KAMA mechanism to chronic cough pathways. Trevi holds 24 issued US and foreign patents covering formulations and methods of use, with a key composition-of-matter patent extending protection to 2039. There are currently no FDA-approved therapies for chronic cough in IPF or RCC, positioning Haduvio as a potential first-in-class therapy in these underserved indications. The addressable patient population is estimated at approximately 140,000 IPF patients and 2-5 million RCC patients in the US.

Trevi is pre-revenue and operates a capital-intensive clinical development business model funded primarily through public equity offerings. The company raised approximately $115.1 million in June 2025 and approximately $150 million in April 2026, bringing pro forma cash to roughly $334 million as of Q1 2026. With a market capitalization of approximately $2.56 billion and 95.76% institutional ownership, Trevi is in a Phase 3 preparation phase, building out commercial leadership (including a new CFO and CCO) in anticipation of a potential first US launch. The company employs 11-50 people and is expected to generate its first commercial revenue following Haduvio's potential regulatory approval, likely via specialty pharmacy distribution to pulmonologists and cough specialists.

Trevi Therapeutics firmographics

Firmographics
Name
Trevi Therapeutics
Legal name
Trevi Therapeutics, Inc.
Website
https://trevitherapeutics.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release nalbuphine therapy targeting chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients, with Phase 3 trials planned to begin in 2026.
Ownership category
akta.pro rank

Trevi Therapeutics industry classification

Industry
Product category
Respiratory Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Chronic cough therapeutics
  • Respiratory biopharmaceuticals
  • Clinical-stage biotechnology
  • Opioid receptor modulators
  • Extended-release drug development

Where Trevi Therapeutics is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Trevi Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels4 records

Trevi Therapeutics product offering

Product offering

Core offering

Trevi Therapeutics develops Haduvio (nalbuphine ER), an investigational oral extended-release therapy that acts as a kappa agonist and mu antagonist (KAMA) targeting opioid receptors along the cough reflex arc both centrally and peripherally. The therapy is being advanced through late-stage clinical development for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC). Haduvio is not yet approved by any regulatory authority.

Product overview

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single investigational therapy, Haduvio (nalbuphine ER), an oral extended-release formulation targeting chronic cough conditions. Haduvio acts as a kappa agonist and mu antagonist (KAMA), working both centrally and peripherally along the cough reflex arc. The company is pursuing development for three indications: chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is not yet approved by any regulatory authority.

Differentiator

Problem solved

Functional benefit

Brands

  • Haduvio: Oral nalbuphine ER therapy for chronic cough conditions including IPF-related chronic cough, non-IPF ILD, and refractory chronic cough. Novel KAMA mechanism acting as kappa agonist and mu antagonist targeting opioid receptors along the cough reflex arc.

Products and services

  • Haduvio (nalbuphine ER) Haduvio is an investigational oral extended-release nalbuphine therapy that acts as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors along the cough reflex arc both centrally and peripherally. It is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The therapy demonstrated statistically significant reductions in cough frequency in Phase 2b CORAL and Phase 2a RIVER trials. Not yet approved by any regulatory authority.

Quantifiable outcome

  • 60.2% reduction in 24-hour cough frequency from baseline at 108mg BID dose (p<0.0001) vs 16.9% for placebo in IPF patients
  • +4 more outcomes

Companies that use Trevi Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Trevi Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Trevi Therapeutics partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Trevi Therapeutics competitors and assessment

Company assessment

Direct peers

  • GlaxoSmithKline (via Bellus Health acquisition): GSK acquired Bellus Health in 2023 to advance camlipixant (BLU-5937), a P2X3 antagonist in Phase 3 development for refractory chronic cough — the most directly competing late-stage chronic cough program to Trevi's Haduvio (nalbuphine ER).
  • Bayer (via NeRRe Therapeutics acquisition): Bayer acquired NeRRe Therapeutics to develop eliapixant and orvepitant for refractory chronic cough; while Bayer later halted the eliapixant program, it remains a direct comparator in the chronic cough therapeutic space alongside GSK's camlipixant.
  • Merck & Co. Merck acquired Afferent Pharmaceuticals and advanced gefapixant (MK-7264) — a P2X3 antagonist — for refractory chronic cough. Although Merck withdrew the original FDA application in 2022, the program represents the most direct historical precedent for Haduvio's commercialization trajectory.
  • Pliant Therapeutics: Pliant Therapeutics is a clinical-stage biotech developing integrin inhibitors (bexotegrast/PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, directly overlapping Trevi's IPF patient population and competing for the same pulmonology specialty prescribing audience.
  • FibroGen: FibroGen developed pamrevlumab (anti-CTGF) for idiopathic pulmonary fibrosis and other fibrotic diseases — sharing Trevi's IPF patient population and clinical development path, providing a relevant benchmark for IPF therapeutic clinical readouts.
  • Bayer (eliapixant program context): Bayer's NeRRe-derived eliapixant (P2X3 antagonist for chronic cough) halted Phase 3 in 2023; Bayer serves as both a precedent (Merck withdrawal) and direct mechanism-class competitor to Haduvio in chronic cough.

Broad incumbents

  • Boehringer Ingelheim: Boehringer Ingelheim markets OFEV (nintedanib) and Esbriet (pirfenidone) — the two FDA-approved therapies for idiopathic pulmonary fibrosis. As the incumbent in Trevi's primary IPF-CC indication, BI is the dominant specialist prescriber base that any Haduvio launch would need to leverage.
  • United Therapeutics: United Therapeutics is a specialty pharmaceutical company with a dominant pulmonary hypertension franchise (Tyvaso, Remodulin) and orphan/rare disease focus, serving as a public-market comparable for capital-efficient pulmonary specialty pharma business models.
  • Insmed: Insmed is a specialty pulmonary pharmaceutical company (brensocatib for bronchiectasis, ARIKAYCE for NTM lung infection) with a similar orphan/rare pulmonary disease commercialization playbook and late-stage clinical assets targeting underserved pulmonary indications.

Emerging players

  • Shionogi (chronic cough pipeline): Shionogi has historically been active in cough therapeutics (codeine-based formulations and novel cough candidates) in Asia and selectively in the US, representing a partial-overlap chronic cough competitor with regional strength.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Trevi Therapeutics social profiles

Digital presence

Trevi Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trevi Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Trevi Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trevi Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trevi Therapeutics

What does Trevi Therapeutics do?

Trevi Therapeutics develops Haduvio (nalbuphine ER), an investigational oral extended-release therapy that acts as a kappa agonist and mu antagonist (KAMA) targeting opioid receptors along the cough reflex arc both centrally and peripherally. The therapy is being advanced through late-stage clinical development for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC). Haduvio is not yet approved by any regulatory authority.

Is Trevi Therapeutics a public or private company?

Trevi Therapeutics is a public company. It is classified as public and is currently operating.

When was Trevi Therapeutics founded?

Trevi Therapeutics was founded in 2011. It employs 11 to 50 people.

Where is Trevi Therapeutics based?

Trevi Therapeutics is headquartered in New Haven, United States, in the North America region.

Who are Trevi Therapeutics's main competitors?

Direct peers on record are GlaxoSmithKline (via Bellus Health acquisition), Bayer (via NeRRe Therapeutics acquisition), Merck & Co., Pliant Therapeutics, FibroGen and Bayer (eliapixant program context). Broad incumbents are Boehringer Ingelheim, United Therapeutics and Insmed. Shionogi (chronic cough pipeline) is listed as an emerging player.

Does Trevi Therapeutics have an API?

No public API is recorded for Trevi Therapeutics.

What industry is Trevi Therapeutics in?

Trevi Therapeutics's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaTrevi Therapeutics: The P2X3 Collapse Leaves Haduvio Standing Alone In Chronic CoughTrevi Therapeutics' Haduvio program faces a P2X3 efficacy ceiling, but its dual-acting mechanism and strong cash position ($299.4M) support funding through 2030. The company is alone in chronic cough indications, with OCEAN-1 and OCEAN-2 trials underway and a Phase 2b LAKE trial ongoing. Haduvio's IPF and non-IPF ILD indications offer potential revenue, with RCC as a growth driver.American Banking and Market NewsTrevi Therapeutics, Inc. $TRVI Holdings Lessened by Fifth Third BancorpFifth Third Bancorp reduced its Trevi Therapeutics stake by 19.6% in Q3, selling 51,004 shares and leaving with 209,640 shares worth $3,002,000. Director Michael Heffernan sold 39,473 shares at $15.09, and analysts rate the stock a Moderate Buy with a $28.09 target.Investing.comTrevi at Stifel 2026 Healthcare Conference 2026: cough focus sharpensTrevi Therapeutics presented at Stifel's 2026 Healthcare Conference, stating it is the only active operator in chronic cough after GSK's BELLUS program failed. Its Phase IIb refractory chronic cough trial's sample size re-estimation is expected in early Q1, with possible expansion up to 52 patients. The company expects important data in 2027.Simply Wall StFDA Feedback And Cash Runway Might Change The Case For Investing In Trevi Therapeutics StockTrevi Therapeutics reported a Q3 2026 net loss of $21.45 million and a nine-month loss of $52.44 million, with no product revenue. The company holds about $299 million in cash, extending its runway into 2030, and received supportive FDA feedback on Haduvio's chronic cough programs. The key near-term catalyst remains successful readouts from OCEAN IPF chronic cough trials.Seeking AlphaTrevi outlines non-IPF-ILD Phase II start in Q1 2027 as cash runway extends into 2030 (NASDAQ:TRVI)Trevi Therapeutics outlined a non-IPF-ILD Phase II dose-ranging study of about 120 patients, planned to start in Q1 2027 with topline data in H1 2028. The company reiterated OCEAN-2 topline in H2 2027 and OCEAN-1 in H1 2028, and reported $299 million in cash with a runway into 2030.BenzingaTrevi Therapeutics Q3 2026 Earnings Call Transcript - Trevi Therapeutics (NASDAQ:TRVI)Trevi Therapeutics reported Q3 2026 results, ending with $299 million in cash and a runway into 2030. The company initiated OCEAN-1 and OCEAN-2 trials for IPF-related chronic cough, with OCEAN-2 reading out in H2 2027 and OCEAN-1 in H1 2028. The LAKE Phase 2b trial for refractory chronic cough includes a sample-size re-estimation, with results expected in early 2027.Business & FinancialTrevi Therapeutics Reports Third Quarter 2026 Financial Results And Provides Business UpdatesTrevi Therapeutics reported Q3 2026 financial results, including a net loss of $21.5 million and $299.4 million in cash. The company initiated Phase 3 OCEAN-2 for IPF-related chronic cough and expects a Phase 2 dose-ranging trial for non-IPF ILD in Q1 2027.American Banking and Market NewsCandriam S.C.A. Purchases 341,885 Shares of Trevi Therapeutics, Inc. $TRVICandriam S.C.A. increased its Trevi Therapeutics stake by 35.4% in Q3, buying 341,885 shares to own 1,308,104 shares (0.92% of the company). Director Michael Heffernan sold 39,473 shares at $15.09, reducing his stake by 86.14%. Analysts rate the stock a Moderate Buy with an average price target of $27.08.American Banking and Market NewsTrevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on MondayTrevi Therapeutics will announce Q3 2026 earnings after market close on November 9th, with analysts expecting a loss of $0.1317 per share. The company's stock opened at $14.33, and analysts have set a consensus price target of $27.08. The company's lead product candidate is Haduvio, an oral nalbuphine formulation.YahooTrevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book ValueTrevi Therapeutics' stock trades at about 6.0 times book value, versus an industry average of 1.9 times and a peer group of 2.8 times. The company's heavy R&D funding phase and lack of earnings anchor the valuation, leaving investors to decide if the pipeline justifies the premium.